Skip to main content

One of Asia’s Stocks Laggards Still a No Go at Jefferies

One of Asia’s Stocks Laggards Still a No Go at Jefferies(Bloomberg) -- Investors looking for rebound candidates heading into 2020 should keep Malaysia off their lists, according to Jefferies Financial Group Inc.The MSCI Malaysia Index has lost 15% since the surprise election victory of Mahathir Mohamad in May 2018, lagging behind the wider MSCI Asia Pacific ex-Japan Index. And it’s still too soon to buy the shares. Jefferies is maintaining its underweight position after first downgrading the nation following last year’s vote.At the time, the reason for the downgrade was “concern that the return of Mahathir would lead to a policy-driven disruption of the positive trend which had been driving the Malaysian economy: That was mainland Chinese investment,” Christopher Wood, Jefferies’s global head of equity strategy, wrote in a Nov. 28 note. “This is essentially what has since happened.”Foreign direct investment inflows to Malaysia from China plummeted to 19 million ringgit ($4.6 million) in the first half of 2019, from more than 700 million ringgit in 2018, according to data from the country’s central bank.Meanwhile, several additional metrics spell caution. First, Malaysia has seen seven straight quarters of profit downgrades, with the 2019 earnings-per-share consensus at MSCI Malaysia Index companies down 21% since April 2018, Wood said. Second, housing starts have fallen and home prices have weakened, coinciding with the slowdown in Chinese investment, he wrote.And finally, don’t ignore politics in “Asia’s most politicised stock market.” Mahathir’s ruling alliance lost a by-election to the main opposition coalition earlier this month in what could be seen as a rebuke to the prime minister, Wood said. On the bright side, a general election doesn’t need to be held until 2023.Stock-Market SummaryMSCI Asia Pacific Index down 0.7%Japan’s Topix index down 0.2%; Nikkei 225 down 0.2%Hong Kong’s Hang Seng Index down 2%; Hang Seng China Enterprises down 2.4%; Shanghai Composite down 0.6%; CSI 300 down 1%Taiwan’s Taiex index down 1%South Korea’s Kospi index down 1.3%; Kospi 200 down 1.4%Australia’s S&P/ASX 200 little changed; New Zealand’s S&P/NZX 50 up 1%India’s S&P BSE Sensex Index down 0.5%; NSE Nifty 50 down 0.4%Singapore’s Straits Times Index down 0.4%; Malaysia’s KLCI down 0.8%; Philippine Stock Exchange Index down 0.7%; Jakarta Composite up 0.8%; Thailand’s SET down 0.6%; Vietnam’s VN Index up 0.2%S&P 500 e-mini futures down 0.3% after index closed up 0.4% in last session\--With assistance from Yudith Ho.To contact the reporter on this story: Eric Lam in Hong Kong at elam87@bloomberg.netTo contact the editors responsible for this story: Christopher Anstey at canstey@bloomberg.net, Cecile Vannucci, Margo TowieFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.




from Yahoo Finance https://ift.tt/33rJhKM

Comments

Popular posts from this blog

Photo finish: Crashing sales force Olympus to sell iconic camera business

Sometimes, the vicissitudes of capitalism force companies to exit the businesses for which they’re best known. Olympus, once a leading light in the photography industry, is now joining that list. On Wednesday, the company said it planned to quit its 84-year-old camera business. The imaging giant, known for its once-pervasive digital cameras, agreed to sell off the declining unit by year’s end. Japan Industrial Partners, a private equity firm best known for buying Sony’s struggling Vaio computer line in 2014, agreed to purchase the business. Terms of the deal were not disclosed. A glance at Olympus’s financial statements provides all the rationale for the divestiture; as at rival manufacturers, camera sales have plummeted over the past decade. For the fiscal year ended March 31, Olympus’s camera unit declined 10% versus the year prior to  ¥43.6 billion, or $407 million. The unit’s sales have collapsed by three-quarters from a decade ago, when the company brought in ¥175 billion, or $

WHO says common steroids can slash death risk for the sickest coronavirus patients

Our mission to help you navigate the new normal is fueled by subscribers. To enjoy unlimited access to our journalism,  subscribe today . An old drug can learn new tricks during the coronavirus pandemic. That’s the main takeaway from the World Health Organization (WHO) in a new analysis of corticosteroids—a class of drugs which have existed for dozens of years and are far cheaper than new, experimental COVID treatments in development—suggesting that drugs like dexamethasone can slash the chances of COVID-19 related deaths by as much as 35% in the sickest patients. The WHO analysis of coronavirus drugs encompassed seven separate studies. And while an analysis of this sort—what’s called a “meta-analysis”—isn’t as rigorous as other types of trials like a randomized controlled study, the data are compelling. Corticosteroids have a very different action mechanism from many of the other coronavirus drugs in development. COVID-19 is a peculiar disease. Some who have been infected may be